Grace Therapeutics (GRCE) Competitors

Grace Therapeutics logo
$1.70 -0.03 (-1.45%)
Closing price 03:58 PM Eastern
Extended Trading
$1.70 -0.01 (-0.29%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRCE vs. SBTX, LENZ, MENS, CRDL, and DERM

Should you buy Grace Therapeutics stock or one of its competitors? Grace Therapeutics's main competitors and comparable companies include Silverback Therapeutics (SBTX), LENZ Therapeutics (LENZ), Jyong Biotech (MENS), Cardiol Therapeutics (CRDL), and Journey Medical (DERM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Grace Therapeutics compare to Silverback Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

In the previous week, Grace Therapeutics had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 2 mentions for Grace Therapeutics and 1 mentions for Silverback Therapeutics. Grace Therapeutics' average media sentiment score of 0.60 beat Silverback Therapeutics' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Grace Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Silverback Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Grace Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Grace Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 251.91%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Grace Therapeutics is more favorable than Silverback Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grace TherapeuticsN/AN/A-$7.79M-$1.23N/A
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A

Silverback Therapeutics' return on equity of -29.62% beat Grace Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Grace TherapeuticsN/A -37.00% -35.53%
Silverback Therapeutics N/A -29.62%-28.20%

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Grace Therapeutics beats Silverback Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

LENZ Therapeutics currently has a consensus target price of $14.75, indicating a potential upside of 384.40%. Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 251.91%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe LENZ Therapeutics is more favorable than Grace Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, LENZ Therapeutics and LENZ Therapeutics both had 2 articles in the media. Grace Therapeutics' average media sentiment score of 0.60 beat LENZ Therapeutics' score of 0.18 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Grace Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Grace Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ Therapeutics$19.09M5.01-$82.13M-$4.49N/A
Grace TherapeuticsN/AN/A-$7.79M-$1.23N/A

LENZ Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Grace Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -1,134.97%. Grace Therapeutics' return on equity of -37.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ Therapeutics-1,134.97% -59.56% -54.75%
Grace Therapeutics N/A -37.00%-35.53%

Summary

LENZ Therapeutics and Grace Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Grace Therapeutics compare to Jyong Biotech?

Grace Therapeutics (NASDAQ:GRCE) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Grace Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 251.91%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Grace Therapeutics is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Jyong Biotech's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Grace TherapeuticsN/A -37.00% -35.53%
Jyong Biotech N/A N/A N/A

Grace Therapeutics has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market.

In the previous week, Grace Therapeutics had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for Jyong Biotech. Grace Therapeutics' average media sentiment score of 0.60 beat Jyong Biotech's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Grace Therapeutics Positive
Jyong Biotech Neutral

6.1% of Grace Therapeutics shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grace TherapeuticsN/AN/A-$7.79M-$1.23N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

Summary

Grace Therapeutics beats Jyong Biotech on 7 of the 11 factors compared between the two stocks.

How does Grace Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

In the previous week, Cardiol Therapeutics had 8 more articles in the media than Grace Therapeutics. MarketBeat recorded 10 mentions for Cardiol Therapeutics and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.60 beat Cardiol Therapeutics' score of -0.29 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiol Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Grace Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cardiol Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 1,049.43%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 251.91%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Grace Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Grace Therapeutics' return on equity of -37.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -159.81% -127.69%
Grace Therapeutics N/A -37.00%-35.53%

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-$24.20M-$0.24N/A
Grace TherapeuticsN/AN/A-$7.79M-$1.23N/A

Summary

Cardiol Therapeutics beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Grace Therapeutics compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Grace Therapeutics has lower revenue, but higher earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Journey Medical$61.86M1.50-$11.43M-$0.18N/A
Grace TherapeuticsN/AN/A-$7.79M-$1.23N/A

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Journey Medical has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Journey Medical presently has a consensus price target of $13.00, suggesting a potential upside of 295.62%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 251.91%. Given Journey Medical's higher possible upside, equities analysts clearly believe Journey Medical is more favorable than Grace Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Grace Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -7.34%. Journey Medical's return on equity of -16.07% beat Grace Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Journey Medical-7.34% -16.07% -5.26%
Grace Therapeutics N/A -37.00%-35.53%

In the previous week, Journey Medical had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for Journey Medical and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.60 beat Journey Medical's score of -0.09 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Journey Medical
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Grace Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Journey Medical beats Grace Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRCE vs. The Competition

MetricGrace TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$35.87M$13.08B$7.42B$10.86B
Dividend YieldN/A2.60%2.48%4.74%
P/E Ratio-1.3927.3332.4528.84
Price / SalesN/A6.568.085.38
Price / CashN/A15.5320.7221.66
Price / Book0.655.164.313.50
Net Income-$7.79M$2.87B$3.51B$394.12M
7 Day Performance-5.80%-7.16%-7.89%-8.87%
1 Month Performance-13.89%-9.53%-10.43%-11.97%
1 Year Performance-45.70%-8.08%-2.77%-9.56%

Grace Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRCE
Grace Therapeutics
1.8755 of 5 stars
$1.71
-1.4%
$6.00
+251.9%
-44.6%$35.87MN/AN/A5
SBTX
Silverback Therapeutics
N/A$3.81
-3.5%
N/A-47.9%$137.38MN/AN/A83
LENZ
LENZ Therapeutics
3.2505 of 5 stars
$4.13
+1.0%
$14.75
+257.1%
-88.3%$128.51M$19.09MN/A152
MENS
Jyong Biotech
N/A$1.76
+4.8%
N/A-94.0%$127.73MN/AN/A27
CRDL
Cardiol Therapeutics
2.36 of 5 stars
$1.00
-3.8%
$10.00
+900.0%
-11.4%$126.48MN/AN/A18

Related Companies and Tools


This page (NASDAQ:GRCE) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners